SCHEMBL6060955

SCHEMBL6060955

C#C/C=C\C#C[Si](C)(C)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6060957 1.00
SCHEMBL8577452 0.81
SCHEMBL8577455 0.81
SCHEMBL8575836 0.74
SCHEMBL8575843 0.74
SCHEMBL8574657 0.72
SCHEMBL9233132 0.68
SCHEMBL2161868 0.64
SCHEMBL2161865 0.64
Bromide SCHEMBL28607029 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091240-B2 Tubulin binding ligands and corresponding prodrug constructs OXIGENE, INC. (US) 2006-08-15 US disclosed
US-20040044059-A1 Destroying tumor cell vasculation; antitumor agents; anticancer agents MATEON THERAPEUTICS, INC. 2004-03-04 US disclosed
US-6593374-B2 Such as 3-(3'4'5'-trimethoxybenzoyl)-2-(3'benzylphosphate 4'methoxyphenyl)-6-methoxybenzo(b)thiophene; functionalized to prepare phosphate esters, phosphate salts, and phosphoramidates useful as antitumor agents BAYLOR UNIVERSITY 2003-07-15 US disclosed
US-20020055643-A1 Tubulin binding ligands and corresponding prodrug constructs MATEON THERAPEUTICS, INC. 2002-05-09 US disclosed
WO-1996003124-A9 DYNEMICIN ANALOGS 1996-03-14 WO disclosed
WO-1996003124-A1 DYNEMICIN ANALOGS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1996-02-08 WO disclosed